Introduction
The BCR-ABL oncogene is a fusion gene that characterizes the neoplastic clone of patients with chronic myeloid leukemia (CML) as well as occasional patients presenting with acute lymphoblastic or myeloid leukemia. 1, 2 The BCR-ABL fusion gene encodes a 210 kDa oncoprotein (p210 BCR-ABL ) 3 with constitutively active tyrosine kinase activity 4 and a predominantly cytoplasmic location. 5 Forced expression of BCR-ABL in primitive murine hematopoietic cells results in the development of a transplantable disease that displays many of the biologic and biochemical features of human BCR-ABL þ leukemia. 6 However, an analogous model of CML based on the transplantation of BCR-ABL-transduced naïve human hematopoietic cells into suitable xenogeneic hosts has not been described previously. Here, we show that primitive human cord blood (CB) cells transduced with the same type of BCR-ABL vector found to cause leukemia in primary murine cells rapidly and durably repopulated the bone marrow (BM) of intravenously injected, nonobese diabetic-severe combined immunodeficiency (NOD/ SCID) or NOD/SCID-b2microglobulin À/À (NOD/SCID-b2m À/À ) mice. In both hosts, the transduced cells displayed a consistently skewed pattern of differentiation occasionally with evidence of disease progression after several months.
Materials and methods

Mice
NOD/SCID and NOD/SCID-b2m
À/À mice were bred and maintained in our facility under microisolation conditions, irradiated (with 350 cGy of 137 Cs g-rays) at 8-10 weeks of age, transplanted and the presence of regenerated human cells assessed in serial BM aspirates as described. 7 
Virus production and transduction of CB cells
Helper-free virus preparations were obtained by transfecting amphotropic Phoenix packaging cells 8 either with an MSCV-BCR-ABL-IRES-GFP vector (P210) containing a full-length b3a2 P210 BCR-ABL cDNA or with a control MSCV-IRES-GFP vector (MIG, from K Humphries, Terry Fox Laboratory, Vancouver, BC, Canada). 9 Virus-containing medium (VCM) was harvested 32 to 72 h later, filtered, titered by analysis of GFP expression in NIH 3T3 cells (P210 ¼ 1À5 Â 10 5 /ml and MIG ¼ 5À9 Â 10 5 /ml) and then used directly to transduce CD34 þ cell-enriched preparations of CB cells as described. 9 The CB cells were obtained with informed consent according to institutional guidelines. Total cell numbers at the end of the infection procedure were approximately the same as the original numbers of cells used to initiate the transduction protocol. The majority of the cells recovered from these transduction cultures were injected intravenously into mice without any attempt to select transduced cells. Additional aliquots were plated in methylcellulose assays to quantify erythroid and granulopoietic colony-forming activity 9 and also in fresh liquid medium containing the same growth factors as used in the transduction protocol to allow gene transfer efficiencies to the CD34 þ cells to be measured by FACS 48 h later (see below).
Flow cytometry
Viable (propidium iodide-negative (PI À )) GFP þ and GFP À CD34 þ cells detectable 48 h after transduction of the CB cells were identified on a FACScalibur using Cell Quest software (Becton Dickinson, San Jose, CA, USA) after staining the cells with a CD34-PE antibody (Becton Dickinson) using gates that excluded 499.9% of cells stained with an irrelevant antibody labeled with phycoerythrin. 10 Repopulation of mice with human cells and detection of the specific lineages produced were determined from FACS analyses of 2 Â 10 4 PI À cells in BM aspirates after lysis of the RBCs with ammonium chloride (StemCell Technologies, Vancouver, BC, Canada) and staining with directly labeled antibodies against 'lineage' (lin) human antigens as described. 7 Reverse transcriptase (RT)-PCR analyses RNA was extracted from 10 4 human GFP þ cells isolated by FACS from BM aspirates obtained from the transplanted mice. The RT reaction was performed in 20 ml volumes with superscript II RNase H À reverse transcriptase (GIBCO/BRL, Rockville, MD, USA) using random hexamer oligonucleotides as primers (Pharmacia, Baie d'Urfe, PQ, Canada) and 5 ml of the RT reaction then used for PCR amplification of BCR-ABL and GAPDH sequences as described. 11 
Southern blot analysis
High molecular weight DNA was isolated from the spleens of mice transplanted with P210-or MIG-transduced cells using DNAzol (GIBCO/BRL). DNA (15 mg) was digested with EcoRI, electrophoresed and transferred to a nylon membrane that was then hybridized with a GFP probe derived from the retroviral vector. A BCR-ABL cDNA was used to confirm the presence of an intact BCR-ABL gene.
Western analyses
Aliquots of 10 5 cells were lysed in phosphorylation solubilization buffer (50 mmol Hepes buffer, 100 mmol NaF, 10 mmol sodium pyrophosphate, 2 mmol Na 3 VO 4 , 4 mmol EDTA) containing 0.5%. Nonidet P-40 and Western analyses performed as previously described using a mouse monoclonal anti-Abl antibody (8E9, Pharmingen, Mississauga ON, Canada) and an anti-phosphotyrosine antibody (4G10, Upstate Biotechnology, Charlottesville, VA, USA). 9 
Statistical analysis
Results are shown as the mean7s.e.m. Differences between groups were assessed using the two-tailed Student's t-test. À/À mice injected with aliquots of the same transduced CB cell suspensions. Absolute numbers of human cells per four hind leg bones were calculated by multiplying the percentages of these detected in BM aspirates by previously determined estimates of the total cellularity of two femurs and two tibias of similarly transplanted NOD/SCID and NOD/SCID-b2m À/À mice assessed over the same time frame. There were no significant differences between the mean levels of total or GFP þ human cells for either vector or host used (P40.05).
Results
BCR-ABL
mediately after their exposure to P210 or control (MIG) VCM. In vitro analyses indicated that 672 and 1776%, respectively, of the CD34 þ cells had been transduced (ie % of CD34 þ cells 2 days post-transduction that were GFP þ ). The difference in these values is consistent with the B2-3-fold difference in the titers of the P210 and MIG VCM used in these experiments. In vitro progenitor assays showed a decreased yield of granulocyte/ macrophage colonies (B2-fold) from the P210-transduced cells and a correspondingly increased production of erythroid colonies (B2-fold) relative to the MIG-transduced cells (data not shown), as noted previously. 9 All of the transplanted mice in these experiments were repopulated with transduced (GFP þ ) human CD45/71 þ cells. The overall numbers of these were not significantly different in the recipients of P210-and MIG-transduced cells throughout 5-6 months of follow-up (Figure 1) . RT-PCR analysis of FACSsorted human cells obtained from recipients of P210-transduced cells (10 mice studied) showed BCR-ABL transcripts were consistently detectable and were absent from the regenerated progeny of transplanted MIG-transduced cells (five mice studied, see Figure 2 ).
Although the total numbers of GFP þ cells generated from the P210-and MIG-transduced CB cells were similar, within 6 weeks, the proportions of these belonging to specific lineages had become markedly different. By this time, the majority of the human cells present in the recipients of control cells were Figure 3a and Supplementary Figure 1) . In contrast, by 6 weeks posttransplant, the proportion (and yield) of cells produced by the P210-transduced CB cells that were B-lymphoid was significantly (Po0.05) and permanently reduced, and the proportion (and number) of myeloid cells was increased in both host genotypes. The production of all three major myeloid lineages from the P210-transduced cells was enhanced, but the most dramatic and consistent change was a prolonged and increasing output of erythroid (glycophorin A þ ) cells, with occasional increases also in the megakaryopoietic (CD41 þ ) lineage. Importantly, the complement of mature human cells produced by the nontransduced cells regenerated in the same mice that contained P210-transduced cells was normal (Figure 3a) . Thus, the abnormal pattern of differentiation exhibited by the P210-transduced cells is cell autonomous.
To investigate whether this skewed differentiation profile was a feature of clonally derived populations of P210-transduced cells, a second series of experiments were performed to generate mice that would be repopulated with single transduced CB cells. Significantly different from the nontransduced cells in the same mice (Po0.05).
BCR-ABL-transduced human cells in vivo
Y Chalandon et al thus precluding their use for more prolonged follow-up. In our experiments, 60% of the original group of mice transplanted were still alive 5-6 months later at which time they were killed. Deaths before that time appeared to be associated either with infections or the anesthetization procedure used to allow BM aspirates to be obtained. However, by 5-6 months, two of the NOD/SCID-b2m À/À mice that had been transplanted with P210-transduced cells were found to have a significantly (Po0.05) elevated WBC count (4 Â 10 6 /ml in both mice vs 1.370.1 Â 10 6 /ml in eight control mice; range in control mice ¼ 0.8À2.0 Â 10 6 /ml, that is, similar to values for untreated mice of these genotypes 13 ). One of the mice with the elevated WBCs also had gross splenomegaly (0.6 g as compared to 0.04-0.08 g in nine control mice assessed at the same time, Figure 4a ). Enlarged spleens (B3-fold at 0.2 g) were also seen in two other NOD/SCID-b2m À/À recipients of P210-transduced cells, although neither of these had elevated WBC counts. No abnormalities were seen in any of the mice injected with MIG-transduced cells.
FACS analysis of the spleen cells from the mouse with the most pronounced splenomegaly showed these were mostly P210-transduced (GFP þ ) human cells (76%), with an erythroid (human glycophorin A þ ) phenotype, although small numbers of GFP þ human CD15 þ (granulopoietic) and B-lymphoid (CD19/ 20 þ ) cells were also present (Figure 4b ). Interestingly, in both the BM (Figure 4c ) and the blood (data not shown) of the same mouse, a larger proportion (B20%) of the P210-transduced (GFP þ ) cells were CD15 þ cells suggesting expansion in the spleen of a variant deregulated P210-transduced clone producing primarily erythroid cells. This was supported by Southern analysis of DNA extracted from the spleen cells of this mouse, which contained a single copy of integrated BCR-ABL cDNA (Figure 4d ). Western analysis of protein extracted from the same spleen showed a high level of p210 BCR-ABL with a higher degree of tyrosine phosphorylation than that seen in the Ph þ K562 cell line (Figure 4e ).
Discussion
In this study, we present the first description of the de novo generation of human preleukemic cell populations in an in vivo model using a retroviral vector-mediated BCR-ABL gene transfer strategy. Primary CD34 þ CB cells were used as the target cells into which an MSCV-promoted transgene containing the p210 BCR-ABL and GFP cDNAs were introduced and sublethally irradiated NOD/SCID and NOD/SCID-b2m À/À mice were used as recipients. Mice repopulated with limiting numbers of cells transduced with the P210 vector produced clones of GFP þ cells containing both B-lymphoid and myeloid progeny; thus, providing definitive evidence that very primitive transplantable CB cells with multilineage potential had been targeted. Previous studies have shown that such cells represent a subset of the CD34 þ CD38 À population that have long-term repopulating ability 7, 14, 15 and likely overlap with the cells in which chronic phase CML originates in patients. 16 Interestingly, the relative numbers of cells belonging to the different lineages produced by the P210-transduced cells in vivo was clearly abnormal. B-lineage cell output was markedly reduced and this was frequently accompanied by a sustained enhancement of erythroid and megakaryocytic cell production. The fact that these quantitative perturbations in mature cell output could be demonstrated in single clones as well as bulk transplants of P210-transduced cells demonstrates that they represented the deregulated growth of multipotent cells and not an altered repopulating ability of subsets of multiple types of committed progenitors. The fact that the more prevalent nontransduced human cells proliferating in the same tissues produced a normal repertoire of differentiated progeny further shows that the biological changes exhibited by the P210-transduced cells are intrinsically determined. Thus, in multiple respects, the effects of the introduced BCR-ABL transgene mimic those typical of primary chronic phase CML populations, which also produce fewer B-lymphoid cells and greater numbers of myeloid cells than their normal counterparts. Primary CML populations also typically contain an elevated number of leukemic erythroid progenitors, 19 although an increase in terminally differentiating erythroblasts in chronic phase CML is rare. 20 On the other hand, we have shown that the same transduction protocol and target cells used here results in the display in vitro of a strongly skewed erythroid differentiation activity by the transduced cells. 9 Thus, it is likely that the same BCR-ABL-activated mechanisms are responsible for the similarly perturbed pattern of differentiation exhibited by primitive P210-transduced CB cells proliferating in vivo.
17,18
After 5 to 6 months, evidence of incipient myeloproliferative disease was seen in four mice transplanted with P210-transduced cells. This was manifested by an increased WBC count and/or splenomegaly. In the mouse with the most advanced pathology, it was possible to demonstrate that the splenomegaly was caused by the deregulated amplification of a single clone of human cells. The cells in this clone contained one copy of the BCR-ABL gene and were highly skewed towards an erythroid differentiation program. The level and degree of phosphorylation exhibited by the p210 BCR-ABL expressed in these cells was equivalent to that seen in K562 cells, a cell line developed from a CML patient with blast phase disease that contains multiple copies of the BCR-ABL oncogene 21, 22 and also displays evidence of erythroid differentiation. 23 Thus, some of the features obtained in this in vivo xenograft model are more reminiscent of blast phase CML where higher levels of BCR-ABL expression are typically seen 24, 25 and perturbations of differentiation are usually more exaggerated. The use of a weaker promoter to reduce the level of expression of the introduced BCR-ABL transgene may thus be needed to create a model that more closely approximates the chronic phase of human CML. Support for this possibility is provided by in vitro experiments demonstrating that partial reduction of the p210 BCR-ABL kinase activity in vitro normalizes the pattern of erythroid and granulopoietic differentiation by P210-transduced CB cells proliferating in vitro. 9 Future studies designed to test these possibilities should thus lead to further improvement of this model and add significantly to its utility for evaluating new therapeutics and identifying genes involved in disease progression.
